Anti-EGF receptor therapy
Anti-EGF receptor therapy
复制标题
DOI：
10.1038/sj.pcan.4500488
复制
发表时间：
2000-12
影响因子：
4.8
通讯作者：
G. Blackledge;S. Averbuch;A. Kay.;J. Barton
中科院分区：
文献类型：
--
作者：
G. Blackledge;S. Averbuch;A. Kay.;J. Barton
表皮生长因子受体(EGFR)信号通路参与了许多重要的肿瘤进展过程，包括细胞增殖、细胞凋亡、血管生成和转移扩散。EGFR信号被认为是激素抵抗型前列腺癌重要的细胞生存机制。ZD1839(易瑞沙‘)是一种口服活性、选择性的EGFR酪氨酸激酶抑制剂(EGFR-TKI)，可阻断与促进肿瘤生长有关的信号转导途径。在临床前研究中，ZD1839单独以及与细胞毒剂联合使用，在广泛的肿瘤细胞系和人类肿瘤异种移植瘤中产生了可逆的生长抑制和生长延迟。对晚期疾病患者进行的I期试验的初步结果表明，ZD1839具有可接受的耐受性，对各种肿瘤类型的患者具有良好的临床疗效，包括激素抵抗型前列腺癌，这些患者需要新的治疗策略。
The epidermal growth factor receptor (EGFR) signalling pathway contributes to a number of processes important to tumour progression, including cell proliferation, apoptosis, angiogenesis and metastatic spread. EGFR signalling is thought to be an important cell survival mechanism in hormone-resistant prostate cancer. ZD1839 (Iressa') is an orally active, selective EGFR-tyrosine kinase inhibitor (EGFR-TKI) which blocks signal transduction pathways implicated in promoting cancer growth. In preclinical studies, ZD1839 alone, and in combination with cytotoxic agents, produced reversible growth inhibition and growth delay in a wide range of tumour cell lines and human tumour xenografts. Preliminary results from phase I trials in patients with advanced disease suggest that ZD1839 has an acceptable tolerability profile and promising clinical efficacy in patients with a variety of tumour types, including hormone-resistant prostate cancer, where new treatment strategies are needed.